Table 1.

Treatment plan for the ACS c-SLNs in vivo chemoprevention study in the LSL-Kras^G12D/+; Pdx-1^Cre/+ PDAC mouse model

Group (G) (3 Male + 3 Females/Group)		Treatment Plan (Oral Gavage)	Dose mg/kg (ASP + CUR + SFN)
G1	Saline control	Saline	0
G2	c-SLN vehicle control	Blank c-SLNs (drug free)	0
G3	Low dose of ACS cSLNs	ASP c-SLNs + CUR c-SLNs + SFN	2 + 4.5 + 0.16
G4	Medium dose of ACS cSLNs	ASP c-SLNs + CUR c-SLNs + SFN	20 + 45 + 1.6
G5	High dose of ACS cSLNs	ASP c-SLNs + CUR c-SLNs + SFN	60 + 135 + 4.8